Hatem A Wafa

King's College London

Papers

1

Total Citations

12

H-Index

1

About

Hatem A. Wafa is a leading clinical researcher in ophthalmology, whose work centers on developing innovative treatments for retinal diseases, particularly neovascular age-related macular degeneration (nAMD). His most significant contribution is his pivotal role in the STAR trial, a landmark, randomized, double-masked, sham-controlled study that evaluated stereotactic radiotherapy as a novel therapy for nAMD. This 2024 trial, which has already garnered 12 citations, demonstrated that ionizing radiation can effectively mitigate key pathogenic processes underlying the disease, offering a potential alternative or adjunct to the standard anti-VEGF injections. By addressing the burden of frequent intravitreal injections, Wafa’s research directly tackles a major challenge in managing chronic retinal conditions. His work represents a critical step toward more durable and less invasive treatment options for patients at risk of blindness. With a focus on translating cutting-edge radiation technology into clinical practice, Wafa is shaping the future of retinal care, providing hope for improved outcomes and quality of life for those affected by age-related vision loss.

Research Focus

Key Achievements

1
H-Index
1
Papers
12
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial
12 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 46
🏛 Institutions: King's College London

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago